YMTracker DRIPCalc v2 Launch sale

NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

BOLD | NASDAQ

$2.51 -$0.05 | -1.95%

SIGNAL:

Signal available — unlock to view

|2026-09-01 |F&G 37 |RSI 30.6

Add to favoritesFavorite

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $0.96 - $3.16

2.5 Year BOLD Performance Metrics:

Total Return (with DRIP): -82.4% (-50.07% CAGR)

Total Return (no DRIP): -82.4% (-50.07% CAGR)

Share Price: -82.4% (-50.07% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $1,761

Total Return $ (with DRIP): -$8,239

BOLD Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

BOLD Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

BOLD Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

BOLD - Revenue

BOLD Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Earnings Per Share (EPS)

BOLD EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Net Income

🔓 See the full chart40% off right now · 7-day free trial

BOLD Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

BOLD EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

BOLD Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

BOLD Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

BOLD Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

BOLD Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

BOLD Shares Outstanding CAGR:1Y: 0.42%2Y: 0.96%5Y: -12.60%10Y: 0.00%

BOLD - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

BOLD Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

BOLD Stock-Based Comp CAGR:1Y: 171.29%2Y: 46.67%5Y: -0.17%10Y: 0.00%

BOLD - Expenses

🔓 See the full chart40% off right now · 7-day free trial

BOLD Expenses CAGR:1Y: -20.83%2Y: -84.10%5Y: -57.39%10Y: 0.00%

BOLD - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

BOLD - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

BOLD - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

BOLD - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

BOLD - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

BOLD - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

BOLD - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

BOLD Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

BOLD Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

BOLD Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

BOLD Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

BOLD - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

BOLD Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

BOLD Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

BOLD Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

BOLD Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

BOLD Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

BOLD - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

BOLD Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for BOLD

Based on past 2.5-year performance, here are BOLD growth metrics:

Share price CAGR of -50.07%
Dividend CAGR of +0%

Using BOLD CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	BOLD (DRIP)	BOLD - No DRIP
Current Price	$2.51	$2.51
Start Shares	3,984.06	3,984.06
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	3,984.06	3,984.06
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.01	$2.51
Total Dividends	$0	$0
Final Value	$39	$10,000

Estimated Future Value + Dividends - BOLD

NOTE: Above numbers are our estimate based on BOLD's Dividend and Price CAGR over past 2.5 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Company Info

Boundless Bio, Inc. (BOLD) had its IPO on 2024-03-28, and is traded on NASDAQ stock exchange.

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

BOLD website: https://boundlessbio.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Loading signals…

DCF Model — BOLD

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $2.51

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own BOLD? See every dividend it's paid you

Add your BOLD shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every BOLD dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

See my BOLD payments →

Free plan · up to 5 holdings